

INTERNATIONAL LAW JOURNAL

WHITE BLACK LEGAL LAW JOURNAL

ISSN: 2581-8503

Peer - Reviewed & Refereed Journal

The Law Journal strives to provide a platform for discussion of International as well as National Developments in the Field of Law.

WWW.WHITEBLACKLEGAL.CO.IN

DISCLAIMER

EDITORIAL TEAM

Raju Narayana Swamy (IAS) Indian Administrative Service officer

Dr. Raju Narayana Swamy popularly known as Kerala's Anti Corruption Crusader is the All India Topper of the 1991 batch of the IAS and is currently posted as Principal Secretary to the Government of Kerala . He has earned many accolades as he hit against the political-bureaucrat corruption nexus in India. Dr Swamy holds a B.Tech in Computer Science and Engineering from the IIT Madras and a Ph. D. in Cyber Law from Gujarat National Law University . He also has an LLM (Pro) (with specialization in IPR) as well as three PG Diplomas from the National Law University, Delhi- one in Urban Environmental Management and Law, another in Environmental Law and Policy and a third one in Tourism and Environmental Law. He also holds a post-graduate diploma in IPR from the National Law School, Bengaluru and a professional diploma in Public Procurement from the World Bank.

Dr. R. K. Upadhyay

Dr. R. K. Upadhyay is Registrar, University of Kota (Raj.), Dr Upadhyay obtained LLB , LLM degrees from Banaras Hindu University & Phd from university of Kota.He has succesfully completed UGC sponsored M.R.P for the work in the ares of the various prisoners reforms in the state of the Rajasthan.

Senior Editor

Dr. Neha Mishra

Dr. Neha Mishra is Associate Professor & Associate Dean (Scholarships) in Jindal Global Law School, OP Jindal Global University. She was awarded both her PhD degree and Associate Professor & Associate Dean M.A.; LL.B. (University of Delhi); LL.M.; Ph.D. (NLSIU, Bangalore) LLM from National Law School of India University, Bengaluru; she did her LL.B. from Faculty of Law, Delhi University as well as M.A. and B.A. from Hindu College and DCAC from DU respectively. Neha has been a Visiting Fellow, School of Social Work, Michigan State University, 2016 and invited speaker Panelist at Global Conference, Whitney R. Harris World Law Institute, Washington University in St.Louis, 2015.

Ms. Sumiti Ahuja

Ms. Sumiti Ahuja, Assistant Professor, Faculty of Law, University of Delhi,

Ms. Sumiti Ahuja completed her LL.M. from the Indian Law Institute with specialization in Criminal Law and Corporate Law, and has over nine years of teaching experience. She has done her LL.B. from the Faculty of Law, University of Delhi. She is currently pursuing Ph.D. in the area of Forensics and Law. Prior to joining the teaching profession, she has worked as Research Assistant for projects funded by different agencies of Govt. of India. She has developed various audio-video teaching modules under UGC e-PG Pathshala programme in the area of Criminology, under the aegis of an MHRD Project. Her areas of interest are Criminal Law, Law of Evidence, Interpretation of Statutes, and Clinical Legal Education.

Dr. Navtika Singh Nautiyal

Dr. Navtika Singh Nautiyal presently working as an Assistant Professor in School of law, Forensic Justice and Policy studies at National Forensic Sciences University, Gandhinagar, Gujarat. She has 9 years of Teaching and Research Experience. She has completed her Philosophy of Doctorate in 'Intercountry adoption laws from Uttranchal University, Dehradun' and LLM from Indian Law Institute, New Delhi.

Dr. Rinu Saraswat

Associate Professor at School of Law, Apex University, Jaipur, M.A, LL.M, Ph.D,

Dr. Rinu have 5 yrs of teaching experience in renowned institutions like Jagannath University and Apex University. Participated in more than 20 national and international seminars and conferences and 5 workshops and training programmes.

Dr. Nitesh Saraswat

E.MBA, LL.M, Ph.D, PGDSAPM
Currently working as Assistant Professor at Law Centre II, Faculty of Law, University of Delhi. Dr. Nitesh have 14 years of Teaching, Administrative and research experience in Renowned Institutions like Amity University, Tata Institute of Social Sciences, Jai Narain Vyas University Jodhpur, Jagannath University and Nirma University.
More than 25 Publications in renowned National and International Journals and has authored a Text book on Cr.P.C and Juvenile Delinquency law.

Subhrajit Chanda

BBA. LL.B. (Hons.) (Amity University, Rajasthan); LL. M. (UPES, Dehradun) (Nottingham Trent University, UK); Ph.D. Candidate (G.D. Goenka University)

Subhrajit did his LL.M. in Sports Law, from Nottingham Trent University of United Kingdoms, with international scholarship provided by university; he has also completed another LL.M. in Energy Law from University of Petroleum and Energy Studies, India. He did his B.B.A.LL.B. (Hons.) focussing on International Trade Law.

ABOUT US

WHITE BLACK LEGAL is an open access, peer-reviewed and

refereed journal providededicated to express views on topical legal issues, thereby generating a cross current of ideas on emerging matters. This platform shall also ignite the initiative and desire of young law students to contribute in the field of law. The erudite response of legal luminaries shall be solicited to enable readers to explore challenges that lie before law makers, lawyers and the society at large, in the event of the ever changing social, economic and technological scenario.

With this thought, we hereby present to you

SYNTHETIC BIOLOGY: BALANCING CHALLENGES OF INTELLECTUAL PROPERTY WITH INNOVATION AND ETHICS

AUTHORED BY - RAMIYA SHREE

Abstract

The accelerating pace of synthetic biology, now characterized by the design of biological systems and novel organisms, threatens to severely challenge the prevailing intellectual property regimes. Indeed, though synthetic biology may interface more intensively than any previous technology with biotechnology, there is now an urgent need to reassess how IPRs can be made toefficiently protect and promote innovation in addition to responding to societal and ethical concerns. The abstract discusses strange challenges facing IPR mechanisms presented by synthetic biology in the backdrop of an analysis both on the literature and legal frameworks of late. Major themes include patenting in relation to synthetic life forms, the possibilities of acquiring monopoly over basic biological resources, and the ownership of genetically engineeredorganisms. Therefore, although IPR can indeed be a good incentive for innovation, there is a call to hasten the promotion of a balanced approach toward the issues on biodiversity, public health, and access to technology in synthetic biology. Therefore, a well-balanced IPR framework mustbe there so that these synthetic biology developments will create a societal welfare by establishing a space where innovation would happen responsibly from an ethical standpoint.

Keywords: Synthetic biology, intellectual property, ethics, innovation, global regulation.

Introduction

Synthetic biology is an area which brings together biology, engineering, and computational science. It creates new biological parts, devices, and systems of potentially transformative impactin fields from medicine and agriculture to environmental management. However, these advancements also raise complex challenges in relation to issues of intellectual property rights, ethics, and broader impacts on society. The article articulates key IP and ethical considerations

ofsynthetic biology and examines not only complexities and nuances created in the legal domain but also ethical implications. It also assesses international perspectives on regulation and outlinesa variety of policy responses to determine how synthetic biology might better serve society's needs in moving forward in relation to these technologies.

Literature Review

- Historical perspective on IPR in biotechnology.
- Key cases and global differences (e.g., *Diamond v. Chakrabarty*, TRIPS agreement).
- Ethical debates on commodifying life and dual-use research.
- Current trends in synthetic biology regulations worldwide (e.g., U.S., EU, China)

Research Gap:

Insufficient Global Ethical and Legal Standards

Existing intellectual property (IP) systems, originally designed for traditional biotechnology, fail to address the complexity of synthetic biology, including genetic circuits, artificial genomes, andengineered organisms.

Findings:

1. **Complexity of Synthetic Biology Challenges Traditional IP Systems**
    - Synthetic biology inventions often surpass traditional patent criteria due to their hybrid natureof natural and engineered components.

2. **Ethical Issues Extend Beyond Patents to Fundamental Questions of Life**
    - Synthetic biology raises profound philosophical questions about life and its manipulation,with bioethicists calling for more thoughtful oversight.

3. **Open-Source Platforms Can Address Access Barriers**
    - Initiatives like BioBricks and iGEM show that collaborative, open-source approaches canfacilitate innovation while addressing IP and ethical challenges.

4. **Compulsory Licensing Can Mitigate Public Health Crises**
    - Governments can use compulsory licensing during emergencies (e.g.,

pandemics) to balancepublic health needs and IP rights.

5. **Need for Ethical Oversight and Public Engagement**
   - Establishing ethical review committees, promoting Responsible Research and Innovation(RRI), and engaging the public are vital to ensuring responsible synthetic biology practices.

Intellectual Property Challenges in Synthetic Biology

1.1. Traditional IP Systems and Synthetic Biology

- Patentability criteria for synthetic organisms and genetic circuits.
- Global disparities in patent laws.

1.2. Balancing Innovation with Accessibility

- Examples of restricted access due to patents (e.g., mRNA vaccines, artemisinin).
- Open-source platforms like BioBricks and iGEM.

Ethical Implications

2.1. Philosophical and Social Concerns

- Manipulation of life and "playing God" debates.
- Impact on biodiversity and ecological systems.

2.2. Dual-Use and Biosecurity Risks

- Potential for misuse of synthetic biology technologies.
- Regulatory and institutional safeguards needed.

Case Studies

- Artemisinin synthesis and IP barriers.
- Genetically modified crops: Monopolies and farmers' rights.
- Biofuels and climate solutions facing IP challenges.

Global Regulatory Frameworks

- Comparison of policies in the U.S., EU, and Asia.
- Role of international agreements like TRIPS in harmonizing IP standards.

Synthetic Biology and Intellectual Property

Biotechnology, as well, has long been inextricably linked with controversy over IP law at least since the 1980 landmark Supreme Court of the United States decision in Diamond v. Chakrabarty, which held that genetically modified organisms are patentable. This soon led to the patenting of designed life forms, which progressed rapidly but brought along some ethical issues.IP systems across the world have subsequently had to come to terms with the nature of the synthetic biology inventions that more often than not fall beyond the traditional bounds of patentability. In many instances, the genetic circuits, designed organisms, or artificial genomes associated with such inventions represent new matter and thus surpass the traditional requirements for patentability. While the traditional IP laws make inventions novel, nonobvious, and useful, in synthetic biology, there are parts taken from nature and others engineered. It thus becomes challenging to determine whether such creations meet the patentability criteria. The ethical implications of commodifying life through synthetic manipulation of genetic material have also raised questions over gene patents and proprietary DNA sequences. This has led to various responses from different regions to the IP challenges of synthetic biology. While the United States generally is less restrictive in granting biotech patents, the European Patent Office tends to be stricter, especially for human-genetics-related and embryos. Asia, particularly China, keeps developing biotechnology patents while taking the growing-innovation principle more intensely. Such differences around the globe could seriously affect global cooperation and competition, therefore requiring more harmonized global standards of IP to encourage synthetic biology.

Ethical Dimensions of Synthetic Biology

Synthetic biology raises fundamental philosophical questions of the nature of life. For instance, by synthetically constructing artificial genomes and assembling living cells from non-living parts, scientists challenge conventional meanings of life. Questions have been raised in this regard by bioethicists on whether playing God in the creation of life is across the boundary, for itwould imply tampering with the processes of nature. This, in turn, creates some very deep philosophical questions concerning what humanity is to do when it comes to control of the elements of life and its propensity for consequences that may be beyond human understanding. However, the dual-use nature that comes out really causes a significant biosecurity problem because synthetic biology can develop viruses or microorganisms into causing harm, especially their release either intentionally or even due to an accident. Along with this need to curb misuse

in the form of strict measures for biosecurity, access to dangerous biological agents needs to be regulated, and ethical standards regarding dual-use research need to be set. In most cases, the novelty of synthetic biology will directly translate into innovative applications in environmental management, for example, the development of organisms that can degrade pollutants or produce biofuels. However, biosafety issues would apply to the release of synthetic organisms intonatural ecosystems because they might interact in unpredictable ways with native species, leading to unintended ecological consequences[1]. Besides, if synthetic organisms were to go beyond the confines of controlled settings, they would disrupt local ecosystems-thus the importance of robust biosafety frameworks and containment protocols.

Intellectual Property Rights and Access to Innovation

While IP protections do incentivize innovation, they limit access to necessary technologies. In the pharmaceutical industry, patents on synthetic biology-based drugs push prices up, creating a barrier to life-saving drugs in low-resource geographies. The COVID-19 pandemic highlighted this fact as patents on mRNA technology initially limited vaccine production across manycountries. This scenario really portrays the ethical dilemma between rewarding innovators and ensuring public access to critical health technologies. The first solution to the dilemma would be compulsory licensing where a government allows third parties to manufacture patented technologies without consent by the patent holder. Under some conditions, it might be the only way of managing a situation where public health needs medical innovations fast. For example, ina public health emergency, a country can use compulsory licensing in synthetic biology-based treatments to gain access and treat more people in exchange for balancing IP rights. Other alternative IP models could balance IP rights with access to innovation. There is the open-source biology platform that can balance the issues of IP rights with the openness of innovation. Such innovations as the BioBricks Foundation and iGEM advance open-source tools and standards forsynthetic biology research[2]. They provide for collaboration, and investigators around the world are given the opportunity to draw from shared resources while ensuring intellectual property protection for products likely to be commercially useful. With regards to this, open source biology offers a way of access in synthetic biology to be more equitable.

[1] Li, J., Zhao, H., Zheng, L., & An, W. (2021). Advances in synthetic biology and biosafety governance. Frontiers in bioengineering and biotechnology, 9, 598087.

[2] McLennan, A. (2012). Building with BioBricks: constructing a commons for synthetic biology research. In Intellectual Property and Emerging Technologies. Edward Elgar Publishing.

Examples of Synthetic Biology and Intellectual Property

Artemisinin: an anti-material compound originating from the sweet wormwood plant, has been synthesized using engineered yeast strains thus producing it more efficiently and easier to access.However, IP in these synthetic biology processes will restrict access to artemisinin in malaria-endemic areas. The synthesis of artemisinin is an excellent example of the ethical considerations involved in IP within synthetic biology. Patent protection often seems to be against the greater need for health across the world. A few applications of synthetic biology to agriculture involve producing crops that are resistant to diseases or drought, which would significantly affect global food security. However, patents on genetically modified crops have typically been a concern about monopolies and farmer's rights. Issues such as these have sparked criticisms regarding companies like Monsanto and their patented seeds that restrict farmers' ability to save and replant them. This raises an ethical dilemma on corporate rights versus food access. Synthetic biology is employed in the design of microbes to produce biofuels or clean pollutants. These applications have very high commercial potential but face IP-related barriers that often limit broader adoption. A case study of companies like Synthetic Genomics, that produce biofuel-producing algae, can illustrate how IP policies impact sustainability efforts. As climate concerns intensify, balancing IP rights with environmental goals will become ever more important.

Global Perspectives on Synthetic Biology Regulation

Countries vary significantly in their approaches to regulating synthetic biology. The U.S. concentrates its policies on the promotion of science, in that a measure of innovation sometimes surpasses stern rules of ethical restraint at times. The EU balances public and environmental ethics as part of its policy concerning intellectual property, such as stopping the granting of patents on biotechnologies solely based on ethical considerations. Asia as represented by the giant Asian economy, China, strives to become world leaders in the area of synthetic biology, by striving to introduce both fast innovation and regulation with risk control over issues of bioethics. International agreements, like the Trade-Related Aspects of Intellectual Property Rights (TRIPS), are important in the harmonization of IP standards worldwide. TRIPS has allowed flexibility for public health needs by encouraging compulsory licensing in emergencies[3].International collaboration is therefore important in synthetic biology in ensuring

[3] Smelly, W. (2023). A TRIP around the World: How the TRIPS Agreement Resolves the Intellectual Property Waiver Dispute and Facilitates Global Access to Medicines. Ohio St. J. on Disp. Resol., 39, 203.

equal access to innovations across borders, particularly health-related applications and sustainable development initiatives. Policy recommendations for synthetic biology will call for differentiated IP models that take into consideration not only the ethical but also public health dimensions. For instance, patent limits on such vital medicines as essential ones and genetically modified organisms will strike a balance between corporate interests and societal needs. Such structures could support an inclusive approach to IP in synthetic biology in favor of both innovation and equitable access.

Another way to regulate the possible risks of synthetic biology would be to adopt ethical oversight bodies to monitor synthetic biology research. These institutions may have biosecurity policies, ethical compliance policies, and monitoring dual-use research applications. International cooperation in ethical supervisions would result in a converged view of biosafety and biosecurity, thus eliminating or minimizing the risks of synthetic biology. Open science frameworks, including BioBricks, may open up avenues for peer-to-peer equitable knowledge sharing in synthetic biology. Research partnership models between academia, industry, and public institutions can leverage innovation and access. By supporting open-source initiatives, policymakers could mitigate IP restrictions that may otherwise limit global access to synthetic biology technologies.

Recommendations for future and present problems:

Synthetic biology holds forth promises of revolutionary possibilities cutting across medicine, environmental management, and many more. This promise comes with a set of very complex challenges, ethical, legal, and social, that will require thoughtful, actionable suggestions to guide the field forward. These guidelines are aimed at developing the framework of intellectual property, ethics, biosecurity, and equitable access that fosters innovation while responsible practices are pursued. In doing so, policymakers, scientists, and institutions can promote a sustainable ecosystem for synthetic biology that not only meets societal needs but also global priorities.

1. **Intellectual Property Recommendations-** The most important challenge with the synthesis of biology is that conventional patent systems do not readily fit within the complexity of a designed biological system. Integration between genetic, chemical, and digital components leads toward inventions that do not neatly fall under traditional

categories for intellectual property. New classifications, therefore, or subcategories could be introduced in a custom-tailored system at the patent level to capture these synthetic biological inventions. This would make patent offices process applications in a consistent and fair manner, thus enhancing transparency and predictability in patent decisions. IP frameworks can define the criteria for distinguishing between engineered components and naturally occurring elements. For instance, elements that are patented and mimic natural biological functions should meet higher originality requirements to ensure that only truly novel inventions receive protection. Open-source synthetic biology initiatives such as BioBricks and iGEM share development platforms, allowing for the open sharing of tools and resources. These models promote basic synthetic biology infrastructure so that innovation can grow without barriers created by intellectual property. Develop Licensing Models for Foundational Synthetic Biology Components- Governments and private institutions should create open-source licensing models for foundational synthetic biology components.

In this way, simple tools can be available freely, while the rights of IP would be preserved for thefinal and commercially valuable applications[4].

There must be public and private funding agencies that provide grants for such open-source synthetic biology projects. The funding agency through its support of initiatives like BioBricks, which provides free access to genetic building blocks for the whole world, encourages collaborative working in which duplication of research work would also be reduced. Public-private partnerships could be utilized as a means to pool the strengths of both sectors toward shared goals. For instance, tax breaks or matching grants to encourage governmental and project collaborations that are innovative but socially relevant would be very helpful. It creates shared pools of patents, particularly around critical applications in health that could ease IP disputes and promote expedited access to necessary technologies. In such a situation, various stakeholders could find ways into essential synthetic biology resources, navigating around otherwise restrictive IP regimes to allow for swift innovations in such areas as vaccines, antibiotics, and diagnostics.

2. **Ethical Recommendations**- The ethical complexity in synthetic biology requires that independent review committees be established at the institutional, national, and

[4] Hope, J. E. (2004). Open source biotechnology. Available at SSRN 755244.

international levels to ensure that research meets accepted ethical standards. Establish Guidelines for Ethical Review of Synthetic Biology Research- Ethical committees should establish guidelines on specific issues in synthetic biology, such as gene editing, synthetic organisms, and dual-use research. These guidelines should be conceptualized to guide researchers through ethics that have to do specifically with synthetic biology and those relevant in the maintenance of bioethicalprinciples, such as transparency, public welfare, and environmental protection. The review committees should thus consider engaging perspectives from bioethicists, scientists, policymakers, community representatives, and affected stakeholders. This inclusion of different viewpoints will ensure that ethical considerations touch on both scientific and social implications toward well-balanced decision making. Since synthetic biology has international implications, there is a need for international ethical guidelines that will ensure responsible and culturally sensitive practices. Organizations such as the WHO and UNESCO can spearhead efforts to set global ethical standards. The guidelines must include ethical requirements for synthetic biology, such as protocols for working with dual-use technologies and considerations for environmental release of synthetic organisms.

Public education and communication by ethics committees and regulatory bodies would be required to obtain trust and understanding toward synthetic biology. Straightforward communication of the benefits, risks, and ethical considerations regarding synthetic biology projects must enable the public to learn societal acceptance as well as accountability. Promote RRI. The RRI framework invites scientists to reflect on how their work impacts society, and withwhom they share their work, and to expect and mitigate risks. Synthetic biology researchinstitutions will incorporate RRI in a responsible manner that is based on transparency, inclusion, and responsiveness to societal needs[5]. The researchers should be more proactive in publicengagement and feedback, especially from the communities that may be impacted by the developments of synthetic biology. Funding agencies could provide training programs for synthetic biology researchers on ethical, social, and environmental responsibilities. This would prepare the researchers with the tools and knowledge to carry out ethically sound and socially beneficial research.

[5] Byrne, P. S. (2020). The RRIght Approach to Scientific and Technological Advancement? A Legal Perspective on Responsible Research and Innovation and Synthetic Biology. The University of Manchester (United Kingdom).

3. **Biosecurity Recommendations-** Dual-use potential of synthetic biology: it has the possibilityof both beneficial and harmful application that requires rigorous regulatory safeguards against misuse. Regulatory agencies should establish specific guidelines for dual-use research: specify types of dual-use research to be closely monitored. These guidelines will define what dual-use potential is in synthetic biology and provide a framework to measure the risks and benefits of such research. Synthetic biology institutions must be provided with obligatory biosecurity training. The researchers would be taught to come up with suitable practices that would reduce the risks associated with dual-use research. This would involve instructing on safe handling, ethical issues concerning dual-use research, and ways of preventing undesirable misuse. WHO, WIPO, and the United Nations should take the lead in establishing standards on biosecurity in research into synthetic biology. Such standards could include restrictions on high-risk experiments, containment protocols, and information-sharing mechanisms to prevent bioterrorism.

   The establishment of a global incident reporting system would facilitate institutions in reporting biosecurity breaches or potential misuse of synthetic biology tools in real time. This would facilitate fast identification, addressing, and mitigation of risks through cooperation and proactivity towards biosecurity. Encourage Self-Regulation and Peer Oversight- Encourage voluntary codes of conduct within the scientific community; that would further strengthen biosecurity standards without mandating regulation. Professional organizations should strive to adopt biosecurity standards and ensure members adhere to best practices. A peer review system for synthetic biology projects, particularly those with high biosecurity risks, will encourage responsible practices. High-risk research proposals would therefore be passed through an independent review process that considers the biosecurity implications for accountability and community-based oversight in planning research.

4. **Access and Global Equity Recommendations-** Public Health and Agriculture should embrace Flexible Licensing- Synthetic biology-based innovation can be made more accessible ina low-resource setting by flexible licensing approaches, for instance, tiered pricing or compulsory licensing. Such licenses could ensure that essential medicines or agricultural technologies that come out of synthetic biology are affordable and accessible to the populations that need them most. Rich countries and private industry should encourage technology transfer programs, allowing developing and middle-

income countries to develop and manufacture synthetic biology innovations at home. Funding, technical training, and support for establishing synthetic biology research infrastructure would be some of that support. Socially Responsible IP Models to Implement Institutions could offer social responsibility-driven IP protection so that companies can license their technologies for optimum access.

Tax incentives and preference in terms of granting would be made to such companies bygovernments for taking up socially responsible practices while managing IP. The syntheticbiology companies should introduce CSR policies and practice the ethically sound and just method[6]. This includes commitment to affordability in life-saving treatments, investment in underserved regions, and ensuring that their products address the global health challenges. Open Access to Foundational Research-Open access to foundational research can accelerate innovationand ensure that basic synthetic biology resources are available to the global scientific community. Support for the growth of open-source synthetic biology repositories such as Addgene and the BioBricks.

Conclusion:

Synthetic biology presents an unprecedented opportunity to face pressing global challenges; it, however, carries with it its own set of complex ethical and legal issues. Long-term, with synthetic biology maturing, a fine line will have to be drawn between delicate IP rights and ethics, access to the public. Encouraging open science, ethical oversight, and equitable IP policies will empower society to use synthetic biology responsibly to the benefit of all people in the world.

[6] Fooks, G., Gilmore, A., Collin, J., Holden, C., & Lee, K. (2013). The limits of corporate social responsibility: techniques of neutralization, stakeholder management and political CSR. Journal of business ethics, 112, 283-299.